Cobalt/Salox-Catalyzed Enantioselective Dehydrogenative C–H Alkoxylation and Amination

Abstract

The past decade has witnessed a rapid progress in asymmetric C–H activation. However, the enantioselective C–H alkoxylation and amination with alcohols and free amines remains elusive. Herein, we disclose the first enantioselective dehydrogenative C–H alkoxylation and amination enabled by a simple cobalt/salicyloxazoline (Salox) catalysis. The use of cheap and readily available cobalt(II) salts as catalysts and Saloxs as chiral ligands provides an efficient method to access P-stereogenic compounds in excellent enantioselectivities (up to >99% ee). The practicality of this protocol is demonstrated by gram-scale preparation and further derivatizations of the resulting P-stereogenic phosphinamides, which offering a flexible asymmetric alternative to access P-stereogenic mono- and diphosphine chiral ligands. Preliminary mechanistic studies on the enantioselective C–H alkoxylation reaction suggest that a cobalt(III/IV/II) catalytic cycle might be involved.

Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review)

“…According to recent data, osimertinib, a third-generation inhibitor used to treat non-small cell lung cancer, including those with brain metastases, has a better ability to penetrate through the BBB [34]. A recent study on xenografts from patients with glioblastoma [35] showed the efficacy of osimertinib in controlling cell growth even with no EGFR expression. This, together with data on ability to effectively overcome the BBB, makes osimertinib a promising drug for treatment.…”

Editorial: Diabetic neuropathy and its complications

“…Many diabetic people experience diabetic neuropathy (DN), a frequent and crippling consequence of diabetes. In addition to hyperglycemia, the pathogenesis of DN includes intricate and multiple mechanisms that involve critical intracellular pathways, proinflammatory cytokines, neurons and satellite glial cells (Bishnoi et al, 2011;Jia et al, 2017;Cheng et al, 2021;Chen et al, 2022). This editorial synthesizes insights from four pioneering studies in 2023 that shed new light on the understanding and management of DN.…”